BORTEZOMIB-MELPHALAN-PREDNISONE VERSUS MP AS INITIAL TREATMENT FOR VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

被引：0
|
作者：
Kim, M. K. [1 ]
Kim, K. [2 ]
Yoon, D. H. [3 ]
Suh, C. [3 ]
Moon, J. H. [4 ]
Lee, Y. J. [4 ]
Lee, J. H. [5 ]
Jung, S. -H. [6 ]
Kim, H. J. [7 ]
Bae, S. H. [8 ]
Kim, J. S. [9 ]
Lee, J. -O. [10 ]
Eom, H. S. [11 ]
Lee, W. -S. [12 ]
Kang, H. J. [13 ]
Mun, Y. -C. [14 ]
Do, Y. R. [15 ]
Hyun, M. S. [16 ]
机构：
[1] Yeungnam Univ, Coll Med, Internal Med, Daegu, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Seoul, South Korea
[4] Kyungpook Natl Univ Hosp, Daegu, South Korea
[5] Gachon Univ, Gil Hosp, Incheon, South Korea
[6] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea
[7] Hallym Univ, Sacred Heart Hosp, Anyang, South Korea
[8] Catholic Univ, Coll Med Daegu, Daegu, South Korea
[9] Yonsei Univ, Coll Med, Severance Hosp, Seoul, South Korea
[10] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[11] Natl Canc Ctr Korea, Goyang, South Korea
[12] Busan Paik Hosp, Busan, South Korea
[13] Korea Canc Ctr Hosp, Seoul, South Korea
[14] Ewha Womans Univ, Sch Med, Seoul, South Korea
[15] Keimyung Univ, Sch Med, Daegu, South Korea
[16] Yeungnam Univ Hosp, Deagu, South Korea
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1993
引用
收藏
页码：793 / 793
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation
    Xie, Dan
    Zhang, Peng-Fei
    BMJ OPEN, 2025, 15 (02):
  • [22] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
    Mateos, Maria-Victoria
    Dimopoulos, Meletios A.
    Cavo, Michele
    Suzuki, Kenshi
    Knop, Stefan
    Doyen, Chantal
    Lucio, Paulo
    Nagy, Zsolt
    Pour, Ludek
    Grosicki, Sebastian
    Crepaldi, Andre
    Liberati, Anna Marina
    Campbell, Philip
    Yoon, Sung-Soo
    Iosava, Genadi
    Fujisaki, Tomoaki
    Garg, Mamta
    Iida, Shinsuke
    Blade, Joan
    Ukropec, Jon
    Pei, Huiling
    Van Rampelbergh, Rian
    Kudva, Anupa
    Qi, Ming
    San-Miguel, Jesus
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 785 - 798
  • [23] Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients
    Boccadoro, M.
    Bringhen, S.
    Gaidano, G.
    Ria, R.
    Offidani, M.
    Patriarca, F.
    Nozzoli, C.
    Musto, P.
    Petrucci, M.
    Palumbo, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
    Palumbo, Antonio
    Bringhen, Sara
    Larocca, Alessandra
    Rossi, Davide
    Di Raimondo, Francesco
    Magarotto, Valeria
    Patriarca, Francesca
    Levi, Anna
    Benevolo, Giulia
    Vincelli, Iolanda Donatella
    Grasso, Mariella
    Franceschini, Luca
    Gottardi, Daniela
    Zambello, Renato
    Montefusco, Vittorio
    Falcone, Antonietta Pia
    Omede, Paola
    Marasca, Roberto
    Morabito, Fortunato
    Mina, Roberto
    Guglielmelli, Tommasina
    Nozzoli, Chiara
    Passera, Roberto
    Gaidano, Gianluca
    Offidani, Massimo
    Ria, Roberto
    Petrucci, Maria Teresa
    Musto, Pellegrino
    Boccadoro, Mario
    Cavo, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (07) : 634 - +
  • [25] Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
    Mateos, Maria-Victoria
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Gutierrez, Norma
    Teruel, Ana-Isabel
    de Paz, Raquel
    Garcia-Larana, Jose
    Bengoechea, Enrique
    Martin, Alejandro
    Diaz Mediavilla, Joaquin
    Palomera, Luis
    de Arriba, Felipe
    Gonzalez, Yolanda
    Hernandez, Jose-Mariano
    Sureda, Ana
    Bello, Jose-Luis
    Bargay, Joan
    Penalver, Francisco-Javier
    Ribera, Jose-Maria
    Martin-Mateos, Maria-Luisa
    Garcia-Sanz, Ramon
    Cibeira, Maria-Teresa
    Martin Ramos, Maria-Luisa
    Vidriales, Maria-Belen
    Paiva, Bruno
    Montalban, Maria-Angeles
    Lahuerta, Juan-Jose
    Blade, Joan
    San Miguel, Jesus-Fernando
    LANCET ONCOLOGY, 2010, 11 (10): : 934 - 941
  • [26] Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Lee, Jae Hoon
    Moreau, Philippe
    Niesvizky, Ruben
    Dimopoulos, Meletios
    Hajek, Roman
    Pour, Ludek
    Jurczyszyn, Artur
    Qiu, Lugui
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Osman, Muhtarjan
    Paiva, Bruno
    San-Miguel, Jesus
    BLOOD, 2019, 133 (18) : 1953 - 1963
  • [27] RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF SILTUXIMAB (AN ANTI-IL-6 MAB) AND BORTEZOMIB-MELPHALAN-PREDNISONE VERSUS BORTEZOMIB-MELPHALAN-PREDNISONE IN PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA
    San Miguel, J.
    Blade, J.
    Samoilova, O.
    Shpilberg, O.
    Grosicki, S.
    Maloisel, F.
    Min, C.
    Zarzuela, M.
    Robak, T.
    Khuageva, N.
    Prasad, S.
    Goh, Y.
    Laubach, J.
    Spencer, A.
    Mateos, M.
    Palumbo, A.
    van de Velde, H.
    Uhlar, C.
    Qin, X.
    Xie, H.
    Orlowski, R.
    HAEMATOLOGICA, 2013, 98 : 97 - 97
  • [28] Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study
    Dimopoulos, Meletios A.
    Mateos, Maria-Victoria
    Richardson, Paul G.
    Schlag, Rudolf
    Khuageva, Nuriet K.
    Shpilberg, Ofer
    Kropff, Martin
    Spicka, Ivan
    Palumbo, Antonio
    Wu, Ka Lung
    Esseltine, Dixie-Lee
    Liu, Kevin
    Deraedt, William
    Cakana, Andrew
    van de Velde, Helgi
    San Miguel, Jesus F.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (01) : 23 - 31
  • [29] Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
    San Miguel, Jesus F.
    Schlag, Rudolf
    Khuageva, Nuriet K.
    Dimopoulos, Meletios A.
    Shpilberg, Ofer
    Kropff, Martin
    Spicka, Ivan
    Petrucci, Maria Teresa
    Palumbo, Antonio
    Samoilova, Olga S.
    Dmoszynska, Anna
    Abdulkadyrov, Kudrat M.
    Delforge, Michel
    Jiang, Bin
    Mateos, Maria-Victoria
    Anderson, Kenneth C.
    Esseltine, Dixie-Lee
    Liu, Kevin
    Deraedt, William
    Cakana, Andrew
    van de Velde, Helgi
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 448 - 455
  • [30] Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
    Fu, Weijun
    Bang, Soo-Mee
    Huang, Honghui
    Kim, Kihyun
    Li, Wei
    An, Gang
    Lee, Je-Jung
    Cai, Zhen
    Jin, Jie
    Wang, Yafei
    Chim, Chor Sang
    Carson, Robin
    Liu, Rui
    Zhao, Man
    Chen, Xi
    Cui, Canchan
    Hou, Jian
    Wang, Jianxiang
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 515 - 525
12345